Medpace Holdings Management

Management Kriterienprüfungen 4/4

Medpace Holdings' CEO ist August Troendle , ernannt in Jul 1992, hat eine Amtszeit von 31.92 Jahren. Die jährliche Gesamtvergütung beträgt $1.65M , bestehend aus 49.5% Gehalt und 50.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 17.43% der Aktien des Unternehmens, im Wert von €2.02B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.3 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

August Troendle

Geschäftsführender

US$1.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	49.5%
Amtszeit als Geschäftsführer	31.9yrs
Eigentum des Geschäftsführers	17.4%
Durchschnittliche Amtszeit des Managements	5.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von August Troendle im Vergleich zu den Einnahmen von Medpace Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$312m
Dec 31 2023	US$2m	US$814k	US$283m
Sep 30 2023	n/a	n/a	US$273m
Jun 30 2023	n/a	n/a	US$268m
Mar 31 2023	n/a	n/a	US$257m
Dec 31 2022	US$2m	US$770k	US$245m
Sep 30 2022	n/a	n/a	US$227m
Jun 30 2022	n/a	n/a	US$209m
Mar 31 2022	n/a	n/a	US$199m
Dec 31 2021	US$6m	US$697k	US$181m
Sep 30 2021	n/a	n/a	US$182m
Jun 30 2021	n/a	n/a	US$175m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$4m	US$608k	US$145m
Sep 30 2020	n/a	n/a	US$124m
Jun 30 2020	n/a	n/a	US$107m
Mar 31 2020	n/a	n/a	US$110m
Dec 31 2019	US$8m	US$504k	US$100m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	n/a	n/a	US$88m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$528k	US$420k	US$73m
Sep 30 2018	n/a	n/a	US$61m
Jun 30 2018	n/a	n/a	US$52m
Mar 31 2018	n/a	n/a	US$45m
Dec 31 2017	US$598k	US$419k	US$39m

Vergütung im Vergleich zum Markt: AugustDie Gesamtvergütung ($USD1.65M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD5.00M).

Entschädigung vs. Einkommen: AugustDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

August Troendle (68 yo)

31.9yrs

Amtszeit

US$1,646,031

Vergütung

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
August Troendle	Chairman & CEO	31.9yrs	US$1.65m	17.43% $ 2.0b
Jesse Geiger	President	2.8yrs	US$945.08k	0.070% $ 8.1m
Kevin Brady	CFO & Treasurer	5.3yrs	US$690.48k	0.019% $ 2.3m
Susan Burwig	Executive Vice President of Operations	7.4yrs	US$1.12m	0.024% $ 2.8m
Stephen Ewald	Chief Compliance Officer	12yrs	US$914.64k	0.043% $ 5.0m
Brandon Ebken	Chief Information Officer	3.4yrs	keine Daten	keine Daten
Lauren Morris	Associate Director of Investors Relations	no data	keine Daten	keine Daten
Todd Meyers	Vice President of Business Development & Marketing	no data	keine Daten	keine Daten
John Wynne	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit	no data	keine Daten	keine Daten
Reinilde Heyrman	Chief Medical Officer of Medical Department	1.4yrs	keine Daten	keine Daten
Gina Leisring	Senior Vice President of Clinical Monitoring	no data	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: 01PDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
August Troendle	Chairman & CEO	31.9yrs	US$1.65m	17.43% $ 2.0b
Fred Davenport	Lead Independent Director	5.8yrs	US$264.98k	0.0065% $ 755.7k
Cornelius McCarthy	Independent Director	5.8yrs	US$217.48k	0.017% $ 1.9m
Robert Kraft	Independent Director	7.9yrs	US$227.35k	0.0014% $ 169.4k
Brian Carley	Independent Director	7.9yrs	US$234.97k	0.070% $ 8.2m
Femida Gwadry-Sridhar	Independent Director	1.4yrs	US$258.37k	0% $ 0
Ashley Keating	Independent Director	5.1yrs	US$209.98k	0.00081% $ 94.6k

5.8yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: 01PDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Medpace Holdings Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Chairman & CEO recently sold €23m worth of stock

Executive Vice President of Operations recently sold €3.5m worth of stock

Recent updates

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

New minor risk - Share price stability

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Chairman & CEO recently sold €23m worth of stock

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022)

Executive Vice President of Operations recently sold €3.5m worth of stock

Now 21% undervalued

Chairman & CEO recently sold €20m worth of stock

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022)

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Now 20% undervalued

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Now 21% undervalued

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021)

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

CFO & Treasurer recently sold €440k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought €15m worth of stock

Chairman & CEO recently bought €10m worth of stock

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Lead Independent Director recently bought €64k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold €859k worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

New 90-day high: €121

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021

New 90-day high: €109

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)

Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day high - €110

New 90-day high - €102

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index